In March, two small biotechs partnered to develop a vaccine for COVID-19 using a mechanism called RNA interference (RNAi) – and early data for the drug they ended up developing was positive. So where do things stand now with their vaccine effort, what are the prospects for the future, and which – if either – of the two firms may be a good investment right now? CLICK HERE.
The Current Status – And Future Prospects – Of This COVID-19 Vaccine Partnership
Tags:Biotech CompaniesBiotech InvestmentsBiotech StocksCOVID-19 VaccineInvestment OpportunityRNA InterferenceRNAiSmall Biotechs